Symbinas Pharmaceuticals Inc

Symbinas Pharmaceuticals Inc., based in St. Johns, FL, is a privately held early-stage biopharmaceutical company focused on developing innovative therapies for concussion and traumatic brain injury (TBI). With a mission to significantly improve the lives of patients affected by TBI, Symbinas is advancing two investigational drugs—SMB-603 and SMB-710—leveraging accelerated market entry to address this global medical crisis impacting millions each year.

Guided by a commitment to collaboration, Symbinas integrates unconventional approaches and partnerships with industry leaders to tackle the neuro-pathological changes associated with concussions and TBI. By focusing on enhancing mitochondrial function and inhibiting neuro-inflammation, the company aims to provide long-term treatment solutions for the chronic effects of these injuries, ultimately transforming patient care in this critical area of medicine.

Generated from the website